http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107384867-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2509-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-34 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
| filingDate | 2017-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107384867-B |
| titleOfInvention | Preparation method of tumor tissue TIL cells and special culture medium |
| abstract | The invention relates to a preparation method of tumor tissue TIL cells and a special culture medium, wherein the method comprises the following steps: tumor-side tissue acquisition, cell digestion, cell primary culture, cell subculture and cell collection, wherein the primary culture medium is based on an RPMI1640 culture medium and comprises the following components in concentration: 10% volume of human serum, 20-45ng/ml basic fibroblast growth factor (bFGF), 1-5mg/ml riboflavin, 70-90ng/ml cortisol, 10-25mg/ml monobasic sodium phosphate, 47-62ng/ml recombinant human Leukemia Inhibitory Factor (LIF), 500-800U/ml IL-2; the subculture medium is based on RPMI1640 medium and comprises the following concentration components: 10 percent of human serum, 20-40mmol/L HEPES, 1000-2000U/ml IL-2, 0.03-0.07mmol/L beta-mercaptoethanol and 5-15ng/ml sodium phosphate. The existing culture medium is improved, different culture media are adopted to carry out targeted culture on the TIL cells, the amplification capacity of the TIL cells is improved, the culture period is shortened, the culture complexity is reduced, and the use amount of IL-2 is reduced, so that the toxic reaction is reduced. |
| priorityDate | 2017-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 227.